The role of interleukin-9 in lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1367-1372

  Lv, Xiao ^a   Wang, Xin ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Eosinophils; IL 9; Lymphoma; Macrophages; Mast cell; T regulatory cell

Indexed keywords

CORTICOSTEROID; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; INTERLEUKIN 9 RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P90; TRANSCRIPTION FACTOR FOXP3;

APOPTOSIS; BINDING SITE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL CYCLE S PHASE; CELL INFILTRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA FRAGMENTATION; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; METASTASIS; NK T CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-9; LYMPHOMA; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84879332695     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.745072     Document Type: Review

References (49)

1. Yang Y C, Ricciardi S, Ciarletta A, et al. Expression cloning of cDNA encoding a novel human hematopoietic growth factor: human homologue of murine T-cell growth factor P40. Blood 1989;74 : 1880-1884. (Pubitemid 19269083)
2. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010; 10: 683-687.
3. van Leeuwen BH, Martinson ME, Webb GC, et al. Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood 1989;73:1142-1148. (Pubitemid 19107414)
4. Stassen M, Klein M, Becker M, et al. p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1. Mol Immunol 2007;44:926-933. (Pubitemid 44415002)
5. Chen J, Petrus M, Bryant BR, et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 2008;111 : 5163-5172.
6. Refaat A, Zhou Y, Suzuki S, et al. Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed Thelper 17 cells producing interleukin-9. J Biol Chem 2011;286:21092-21099.
7. Chang HC, Sehra S, Goswami R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010;11:527-534.
8. Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of Thelper 9 cells. Immunity 2010;33:192-202.
9. Renauld JC, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci USA 1992;89:5690-5694.
10. Demoulin J B, Uyttenhove C, Lejeune D, et al. S TAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res 2000; 60: 3971-3977. (Pubitemid 32204594)
11. Zhu YX, Sun HB, Tsang ML, et al. Critical cytoplasmic domains of human interleukin-9 receptor alpha chain in interleukin-9-mediated cell proliferation and signal transduction. J Biol Chem 1997; 272: 21334-21340.
12. Hornakova T, Staerk J, Royer Y, et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 2009;284:6773-6781.
13. Demoulin J B, Louahed J, Dumoutier L, et al. M AP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene 2003;22:1763-1770. (Pubitemid 36513136)
14. Xiao H, Yin T, Wang X Y, et al. Specificity of interleukin-2 receptor gamma chain superfamily cytokines is mediated by insulin receptor substrate-dependent pathway. J Biol Chem 2002;277:8091-8098. (Pubitemid 34968263)
15. Merz H, Houssiau FA, Orscheschek K, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin ' s disease and large cell anaplastic lymphoma. Blood 1991;78:1311-1317.
16. Nagato T, Kobayashi H, Kishibe K, et al. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 2005; 11: 8250-8257. (Pubitemid 41746934)
17. Fischer M, Bijman M, Molin D, et al. I ncreased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin ' s lymphoma. Leukemia 2003; 17: 2513-2516. (Pubitemid 38072592)
18. Bittner C, Merz H, Krokowski M, et al. [New immunotherapeutic approaches for the treatment of anaplastic large cell lymphoma in a mouse model]. Verh Dtsch Ges Pathol 2000; 84: 187-198.
19. Renauld JC, van der Lugt N, Vink A, et al. Th ymic lymphomas in interleukin 9 transgenic mice. Oncogene 1994;9:1327-1332. (Pubitemid 24123649)
20. Merz H, Lange K, Nadrowitz R, et al. [Overexpression of NPMALK induces diff erent types of malignant lymphomas in IL-9 transgenic mice]. Verh Dtsch Ges Pathol 2003; 87: 224-231.
21. Vink A, Renauld J C, Warnier G, et al. Interleukin-9 stimulates in vitro growth of mouse thymic lymphomas. Eur J Immunol 1993;23 : 1134-1138. (Pubitemid 23120177)
22. Gruss HJ, Brach MA, Drexler HG, et al. Interleukin 9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992; 52: 1026-1031.
23. Qiu L, Lai R, Lin Q, et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK anaplastic large-cell lymphoma cells. Blood 2006;108:2407-2415. (Pubitemid 44497526)
24. Renauld J C, Vink A, Louahed J, et al. I nterleukin-9 is a major antiapoptotic factor for thymic lymphomas. Blood 1995; 85: 1300-1305.
25. Shang Y, Kakinuma S, Amasaki Y, et al. Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6 and resistant C3H mice. In Vivo 2008;22:713-720.
26. Lemoli RM, Fortuna A, Tafuri A, et al. Interleukin-9 in human myeloid leukemia cells. Leuk Lymphoma 1997; 26: 563-573. (Pubitemid 27477781)
27. Fontaine RH, Cases O, Lelievre V, et al. IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell Death Diff er 2008;15:1542-1552.
28. Singhera GK, MacRedmond R, Dorscheid DR. Interleukin-9 and-13 inhibit spontaneous and corticosteroid induced apoptosis of normal airway epithelial cells. Exp Lung Res 2008; 34: 579-598.
29. Carbone A, Gloghini A, Cabras A, et al. The germinal centrederived lymphomas seen through their cellular microenvironment. Br J Haematol 2009;145:468-480.
30. Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin ' s lymphoma. Br J Haematol 2002;119:122-124. (Pubitemid 35176509)
31. Hedstrom G, Berglund M, Molin D, et al. Mast cell infiltration is a favourable prognostic factor in diff use large B-cell lymphoma. Br J Haematol 2007;138:68-71. (Pubitemid 46889780)
32. Taskinen M, Karjalainen-Lindsberg ML, Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008; 111: 4664-4667.
33. Stassen M, Arnold M, Hultner L, et al. Murine bone marrowderived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol 2000;164 : 5549-5555. (Pubitemid 30389793)
34. Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine 2004;26:122-130. (Pubitemid 38596922)
35. Matsuzawa S, Sakashita K, Kinoshita T, et al. I L-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 2003;170:3461-3467. (Pubitemid 36359211)
36. Renauld JC, Kermouni A, Vink A, et al. Interleukin-9 and its receptor: involvement in mast cell diff erentiation and T cell oncogenesis. J Leukoc Biol 1995;57:353-360.
37. Hultner L, Druez C, Moeller J, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990;20:1413-1416. (Pubitemid 20206111)
38. Townsend JM, Fallon GP, Matthews JD, et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000;13:573-583.
39. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3 regulatory T cells with improved survival in germinal center-like diff use large B-cell lymphoma, follicular lymphoma and classical Hodgkin' s lymphoma. Haematologica 2008; 93:193-200.
40. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006;442 : 997-1002. (Pubitemid 44330250)
41. Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th 17-driven inflammatory disease. J Exp Med 2009;206:1653-1660.
42. Smith SE, Hoelzinger DB, Dominguez AL, et al. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother 2011; 60: 1775-1787.
43. Elyaman W, Bradshaw E M, Uyttenhove C, et al. I L-9 induces diff erentiation of TH17 cells and enhances function of FoxP3 natural regulatory T cells. Proc Natl Acad Sci USA 2009;106:12885-12890.
44. Glimelius I, Rubin J, Rostgaard K, et al. Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin ' s lymphoma-a population-based study. Eur J Haematol 2011;87:208-216.
45. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin' s lymphoma. N Engl J Med 2010; 362: 875-885.
46. Louahed J, Zhou Y, Maloy W L, et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood 2001;97:1035-1042. (Pubitemid 32154290)
47. Molin D, Glimelius B, Sundstrom C, et al. The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin ' s disease. Leuk Lymphoma 2001; 42: 457-465. (Pubitemid 32725601)
48. Glimelius I, Edstrom A, Amini RM, et al. IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 2006;76:278-283. (Pubitemid 43362935)
49. Merz H, Lange K, Gaiser T, et al. C haracterization of a novel human anaplastic large cell lymphoma cell line tumorigenic in SCID mice. Leuk Lymphoma 2002; 43: 165-172. (Pubitemid 34223986)